2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108506
    Licarbazepine 29331-92-8 99.77%
    Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects.
    Licarbazepine
  • HY-109052
    Atabecestat 1200493-78-2 98.97%
    Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment.
    Atabecestat
  • HY-110018
    N-Arachidonyldopamine 199875-69-9 98.36%
    N-Arachidonyldopamine is a potent and selective endogenous CB1 receptor agonist with a Ki of 250 nM. N-Arachidonyldopamine is also a potent and selective TRPV1 agonist an with EC50 of ~ 50 nM.
    N-Arachidonyldopamine
  • HY-110291
    A-971432 1240308-45-5 99.31%
    A-971432 is a potent, selective and orally active sphingosine-1-phosphate (S1P) receptor 5 agonist with IC50s of .362, >10, 0.006 μM for S1P1, S1P3, S1P5 respectively. A-971432 protects blood–brain barrier (BBB) homeostasis. A-971432 reverses age-related cognitive decline. A-971432 has the potential for the research of alzheimer’s disease or multiple sclerosis .
    A-971432
  • HY-113404
    DL-Dopa 63-84-3
    DL-Dopa is a dopamine precursor. It serves as a substrate for Mushroom Tyrosinase, which oxidizes it to dopaquinone, an intermediate in the DOPA-melanin polymerization process, and this reaction can be detected at 475 nm. DL-Dopa also forms synergistic hydrophobic and π-π stacking interactions with cationic surfactants. Its binding to cetylpyridinium chloride (HY-B1464) is stronger and exhibits better thermodynamic stability than its binding to benzalkonium chloride (HY-B2232). DL-Dopa can compensate for dopamine depletion in the brain and is applicable to research related to Parkinson's disease.
    DL-Dopa
  • HY-115354
    4-Hydroxy alprazolam 30896-57-2 99.0%
    4-Hydroxy alprazolam is a metabolite of Alprazolam. Alprazolam is metabolized primarily by hepatic microsomal oxidation, yielding 4-Hydroxy alprazolam.
    4-Hydroxy alprazolam
  • HY-116477
    URB937 1357160-72-5 99.62%
    URB937 is an orally active and peripherally restricted FAAH inhibitor (IC50=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier).
    URB937
  • HY-116513
    Adrenochrome 54-06-8 99.22%
    Adrenochrome (Adraxone) is an oxidation product of Epinephrine. Adrenochrome is a potent coronary constricting agent in the rat heart. Adrenochrome can be used for neurological disorder research.
    Adrenochrome
  • HY-116578
    Metopimazine 14008-44-7 99.75%
    Metopimazine (EXP999; RP9965) is a phenothiazine, orally available, selective dopamine D2 receptor antagonist that does not penetrate the blood-brain barrier. Metopimazine blocks dopamine D2 receptors in the chemoreceptor trigger zone and the periphery, thereby inhibiting nausea and vomiting. Metopimazine is indicated for chemotherapy-induced nausea and vomiting, and has low central side effects due to its poor brain penetration. The use of metopimazine in acute gastroenteritis may have potential risks.
    Metopimazine
  • HY-117073
    ITH12575 1802013-08-6 98.58%
    ITH12575, a CGP37157 derivative, is a potent and selective mNCX blocker. ITH12575 reduces Ca2+ influx through CALHM1 at low micromolar concentrations.
    ITH12575
  • HY-117292
    DAO-IN-2 39793-31-2
    DAO-IN-2 is a d-amino acid oxidase (DAO) inhibitor (h-DAO IC50 = 245 nM). DAO-IN-2 is a moderate inhibitor of DAAO in vitro and in vivo. DAO-IN-2 can be used to study DAAO-related psychiatric disorders.
    DAO-IN-2
  • HY-117348
    NCC-149 1316652-41-1 99.29%
    NCC-149 is a selective HDAC8 inhibitor and can be used for neural differentiation research.
    NCC-149
  • HY-117709
    BRD6688 1404562-17-9 98.06%
    BRD6688 is a selective HDAC2 inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model.
    BRD6688
  • HY-117822
    BRD0209 1597439-87-6 99.63%
    BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC50 = 19 nM; GSK3β IC50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics (Ki = 4.2 nM, respectively). BRD0209 is a tricyclic pyrazolotetrahydroquinolinone compound. BRD0209 has the potential for the research of mood disorder diseases.
    BRD0209
  • HY-118828
    12-Oxo phytodienoic acid 85551-10-6 ≥99.0%
    12-Oxo phytodienoic acid (12-OPDA) is a plant lipid-derived anti-inflammatory compound. 12-Oxo phytodienoic acid suppresses neuroinflammation by inhibiting Nf-κB and p38 MAPK signaling in Lipopolysaccharides (LPS) (HY-D1056)-activated cells. 12-Oxo phytodienoic acid can be used for neurodegenerative diseases research.
    12-Oxo phytodienoic acid
  • HY-119677
    Oxypertine 153-87-7 99.84%
    Oxypertine (WIN-18501-2) is a neuroprotective agent. Oxypertine shows high affinity for the 5-HT2 and dopamine D2 receptors with Kis of 8.6 nM and 30 nM, respectively. Oxypertine can be used in the research of neurological conditions, such as anxiety and schizophrenia.
    Oxypertine
  • HY-120160
    Darglitazone 141200-24-0 99.19%
    Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research.
    Darglitazone
  • HY-120170
    BMS-466442 1598424-76-0 98.24%
    BMS-466442 is a potent and selective inhibitor of asc-1 (alanine serine cysteine transporter-1), with an IC50 of 11 nM. BMS-466442 inhibits [3H] D-serine uptake into rat brain synaptosomes, with an IC50 of 400 nM. BMS-466442 can be used for schizophrenia research.
    BMS-466442
  • HY-120553
    B-355252 1261576-81-1 99.71%
    B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD).
    B-355252
  • HY-120717
    VU6001966 2009052-76-8 ≥99.0%
    VU6001966 is a brain-penetrant and selective mGlu2 receptor inhibitor. VU6001966 blocks mGlu2 receptor activity, counteracts LY379268 (HY-103558)-mediated blood-brain barrier protection and inflammatory cytokine dampening in microglia under inflammatory conditions. VU6001966 enhances antidepressant effects when combined with Scopolamine (HY-N0296). VU6001966 can be used for the research of major depressive disorder.
    VU6001966
Cat. No. Product Name / Synonyms Application Reactivity